Cargando…

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

BACKGROUND: High-dose (HD) chemotherapy with melphalan and autologous blood stem cell transplantation (ABSCT) for treatment of symptomatic multiple myeloma (MM) on an outpatient basis has been well established in the USA and Canada, whereas in Germany and Western Europe an inpatient setting is the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lisenko, Katharina, Sauer, Sandra, Bruckner, Thomas, Egerer, Gerlinde, Goldschmidt, Hartmut, Hillengass, Jens, Schmier, Johann W., Shah, Sofia, Witzens-Harig, Mathias, Ho, Anthony D., Wuchter, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322605/ https://www.ncbi.nlm.nih.gov/pubmed/28228122 http://dx.doi.org/10.1186/s12885-017-3137-4

Ejemplares similares

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

Quality of Online Information on Multiple Myeloma Available for Laypersons
por: Staemmler, Henrike, et al.
Publicado: (2022)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
por: Lehners, Nicola, et al.
Publicado: (2017)

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma
por: Maatouk, Imad, et al.
Publicado: (2019)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2016)

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation
por: Mosebach, Jennifer, et al.
Publicado: (2018)

Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study
por: Maatouk, Imad, et al.
Publicado: (2018)

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2011)

Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma
por: Neuendorff, Nina Rosa, et al.
Publicado: (2023)

Physical Activity in Multiple Myeloma: A Review of the Current Literature
por: Hillengass, Michaela, et al.
Publicado: (2023)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
por: Schmitt, Thomas, et al.
Publicado: (2010)

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2016)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
por: Witzens-Harig, Mathias, et al.
Publicado: (2013)

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017)

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin
por: Kasper, Bernd, et al.
Publicado: (2009)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(−) T-cells
por: Neuber, Brigitte, et al.
Publicado: (2017)

Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution
por: Sauer, Sandra, et al.
Publicado: (2020)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance—What Information Is out There for Our Patients?
por: Kreutzer, Emma Pauline, et al.
Publicado: (2021)

Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria
por: Wennmann, Markus, et al.
Publicado: (2020)

Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns
por: Wennmann, Markus, et al.
Publicado: (2021)

A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma
por: Schmitt, Thomas, et al.
Publicado: (2011)

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
por: Lehners, Nicola, et al.
Publicado: (2017)

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
por: GroΔ, Jonathan P., et al.
Publicado: (2017)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Flow cytometry‐based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis
por: Lisenko, Katharina, et al.
Publicado: (2016)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Future Directions in Maintenance Therapy in Multiple Myeloma
por: Holstein, Sarah A., et al.
Publicado: (2021)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized Trials
por: Vidal, Liat, et al.
Publicado: (2018)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
por: Boquoi, Amelie, et al.
Publicado: (2023)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kb8o26fms9gj26p1mhj4qi1nm2